On the enzymic defects in hereditary tyrosinemia.
The activity of the enzyme porphobilinogen synthase (EC 4.2.1.24) in erythrocytes from patients with hereditary tyrosinemia was less than 5% of that in a control group and the activity in liver tissue was less than 1% of the reported normal activity. Urine from patients with hereditary tyrosinemia contained an inhibitor that was isolated and identified as succinylacetone (4,6-dioxoheptanoic acid) by gas/liquid chromatography-mass spectrometry. Fresh urine samples contained succinylacetoacetate (3,5-dioxooctanedioic acid) as well as succinylacetone. The inhibition of porphobilinogen synthase explains the high excretion of 5-aminolevulinate observed in hereditary tyrosinemia. Succinylacetone and succinylacetoacetate presumably originate from maleylacetoacetate or fumarylacetoacetate, or both, and their accumulation indicates a block at the fumarylacetoacetase (EC 3.7.1.2) step in the degradation of tyrosine. We suggest that the severe liver and kidney damage in hereditary tyrosinemia may be due to the accumulation of these tyrosine metabolites and that the primary enzyme defect in hereditary tyrosinemia may be decreased activity of fumarylacetoacetase.
D015111:4-Hydroxyphenylpyruvate Dioxygenase / Q000378:metabolism; D000592:Amino Acid Metabolism, Inborn Errors / Q000201:enzymology*; D002264:Carboxylic Acids / Q000652:urine; D004912:Erythrocytes / Q000201:enzymology; D006801:Humans; D007659:Ketones / Q000652:urine; D008099:Liver / Q000201:enzymology; D000623:Porphobilinogen Synthase / Q000037:antagonists & inhibitors / Q000378:metabolism; D014443:Tyrosine / Q000097:blood*
D002264:Carboxylic Acids; D007659:Ketones; D014443:Tyrosine; D015111:4-Hydroxyphenylpyruvate Dioxygenase; D000623:Porphobilinogen Synthase
Biochem J. 1938 Apr;32(4):733-42
16746681
J Biol Chem. 1956 May;220(1):79-91
13319328
Lancet. 1956 Jan 21;270(6908):125-7
13287081
Biochem J. 1955 Dec;61(4):618-29
13276347
J Biol Chem. 1955 Oct;216(2):489-98
13271329
J Pediatr. 1965 Apr;66:670-96
14271358
J Biol Chem. 1961 Nov;236:2835-40
14461395
Science. 1957 Jul 26;126(3265):168
13442665
J Biol Chem. 1977 Jul 25;252(14):5073-84
873932
Biochim Biophys Acta. 1972 Sep 19;284(1):90-100
4627454
Clin Biochem. 1971 Dec;4(4):222-32
5005890
Scand J Clin Lab Invest. 1972 Feb;29(1):115-26
5014992
Acta Paediatr Scand. 1970 Mar;59(2):141-7
5442425
Acta Paediatr Scand. 1969 Jul;58(4):393-6
4390478
J Pharmacol Exp Ther. 1973 Oct;187(1):203-10
4147720
S Afr Med J. 1973 Sep 29;47(38):1735-8
4270402
J Pediatr. 1976 Mar;88(3):434-8
173827
Biochem Pharmacol. 1974 Oct 15;23(20):2785-94
4429585
J Pharmacol Exp Ther. 1973 Oct;187(1):211-7
4746329
J Pharmacol Exp Ther. 1973 Oct;187(1):195-202
4746327
J Pharmacol Exp Ther. 1973 Oct;187(1):185-94
4746326
Clin Chem. 1976 Jan;22(1):49-52
1245060
Clin Chim Acta. 1971 Aug;34(1):113-21
5118723
Pediatrics. 1971 Sep;48(3):393-400
5094340
Acta Chem Scand. 1970;25(1):329-30
5516169
J Pediatr. 1970 Sep;77(3):397-406
5502089
Acta Paediatr Scand. 1969 Jan;58(1):37-48
5789740
Clin Chim Acta. 1969 Feb;23(2):257-63
5764904
J Ment Defic Res. 1968 Dec;12(4):269-81
5729527
Am J Dis Child. 1967 Jan;113(1):31-7
6015903
Am J Med. 1966 Jul;41(1):149-62
5939541